Skip to main content

Table 4 Comparison of the prevalence rate of PPO among the control and intervention groups

From: The impact of a multifaceted intervention to reduce potentially inappropriate prescribing among discharged older adults: a before-and-after study

Type of PPOs according to START criteria Control Group N (%) Intervention group N (%)
Cardiovascular System
  “Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial fibrillation” 2 (0.8) 7 (2.9)
  “Antiplatelet therapy with a documented history of coronary, cerebral or peripheral vascular disease” 10 (4.2) 5 (2.1)
  “Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease” 11 (4.6) 11 (4.6)
  “Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery disease” 30 (12.5)* 16 (6.7)*
  “Beta-blocker with ischaemic heart disease” 22 (9.2) 16 (6.7)
 “Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure” 6 (2.5) 6 (2.5)
Respiratory System
  “Regular inhaled ß2 agonist or antimuscarinic bronchodilator mild to moderate asthma or COPD” 11 (4.6) 17 (7.1)
  “Regular inhaled corticosteroid for moderate-severe asthma or COPD” 10 (4.2) 6 (2.5)
Musculoskeletal System
  “Vitamin D supplements in older people who are housebound or experiencing falls or with osteopenia” 37 (15.4)** 14 (5.8)**
  “Xanthine-oxidase inhibitors with a history of recurrent episodes of gout” 2 (0.8) 3 (1.3)
Endocrine System
  “ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal disease” 20 (8.3) 29 (12.1)
Urogenital System
  “Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary” 9 (3.8) 6 (2.5)
  “5-alpha-reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary” 12 (5.0) 9 (3.8)
  1. COPD chronic obstructive pulmonary disease.
  2. *p = 0.03; **p = 0.001